On Wednesday, February 3, 2016, Aethlon Medical, Inc. (Nasdaq: AEMD), announced that a human treatment study entitled: "A Clinical Safety Study of the Aethlon Hemopurifier® in Patients with Dengue Virus Infection," has been approved by the Institutional Ethics Committee (IEC) at the MAX Super Specialty Hospital in Delhi, India. The Aethlon Hemopurifier is a leading broad-spectrum treatment counter-measure against viral pathogens that are untreatable with or resistant to antiviral drug therapies. Dengue infects approximately 390 million people a year world-wide, 96 million of whom require treatment, according to the World Health Organization (WHO). About 12,500 people die from dengue every year. Initiation of the Aethlon Dengue study is expected this summer, pending final documentation and clearance from the Drug Controller General of India (DCGI). In 2015, the Dengue outbreak in the Delhi region was considered the worst in 20 years. Aethlon also disclosed that in vitro studies conducted by the National Institute of Virology (NIV) have validated the rapid capture of Chikungunya virus by small-scale versions of the Aethlon Hemopurifier. The NIV is a leading infectious disease research center in India, and is designated as a collaborating laboratory of the WHO. Details of the Chikungunya study along with other Hemopurifier in vitro virus validations can be accessed online at: www.aethlonmedical.com/knowledge-center/special-reports/. Like Dengue, Chikungunya has emerged to become a global threat that remains un-addressed with proven antiviral drug therapies. Both viruses are transmitted by the Aedes aegypti mosquito, which also transmits Zika, a virus that was declared a global health threat by the WHO on February 1, 2016. Zika is the most recent of four significant arboviruses that have spread to the Western Hemisphere.
Login Or Register To Read Full Story